Drug intelligence / Profile preview

zilongjin

Development stage
Unknown
Lead developer
Tianjin Pharmaceutical Da Ren Tang Group
Modality
Small Molecules
Administration
Oral
01

Overview

Zilongjin is a traditional Chinese medicine (TCM) compound preparation formulated as a tablet and used primarily as an adjunct therapy for cancer patients, especially those with primary lung cancer experiencing "qi" and "blood" deficiency syndromes during chemotherapy[1][4][8]. It consists of eight herbal ingredients including Astragalus membranaceus (Radix astragali), Angelica sinensis (Chinese angelica), Herba Solani lyrati (Lyrate nightshade), Herba Solani nigra (Long kui cao), Salvia miltiorrhizae radix et rhizoma, and Scutellaria barbatae herba[3][5]. The formulation is designed to support the immune system, alleviate chemotherapy-induced toxicity such as leukopenia and organ damage, improve clinical symptoms, and potentially inhibit tumor growth[2][3][9]. Mechanistic studies suggest that it may exert anti-cancer effects by modulating gene expression related to apoptosis, cell cycle regulation, and MAPK signaling pathways in tumor cells[7][8].

Brand names
ZilongjinZilongjin-8Zilongjin8Zilongjin 8
Other names
Zi Long Jin PianZLJ tablet
02

Targets

AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)FOS (Activator Protein 1)

Beyond the preview

Go deeper on zilongjin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on zilongjin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call